What Medicare Coverage Would Need to Include
For a weight-loss intervention to be broadly accessible through Medicare, it must meet criteria that go well beyond a single clinical trial. The compound needs a formal FDA indication for obesity or a related metabolic condition, not merely a research-use label. It must also demonstrate sustained efficacy and safety in populations that reflect Medicare demographics, older adults, often with multiple comorbidities. Cost-effectiveness analyses, typically derived from large randomised controlled trials and long-term observational data, would need to show that the treatment reduces hard endpoints like cardiovascular events or diabetes progression. Without this, the Centers for Medicare & Medicaid Services (CMS) is unlikely to issue a national coverage determination.
Semaglutide has begun to approach this threshold. The STEP trials (Wilding 2021) provided evidence of 15% body-weight reduction over 68 weeks, and SELECT (Lincoff 2023) showed a 20% reduction in major adverse cardiovascular events in overweight patients with established cardiovascular disease. These data, combined with an FDA approval for chronic weight management, have prompted some Medicare Part D plans to cover semaglutide when prescribed for type 2 diabetes or, more recently, for obesity with cardiovascular risk. However, coverage remains fragmented.
AOD-9604 sits at a very different point on the evidence spectrum. Originally developed as a fragment of human growth hormone, it has been studied primarily for its lipolytic effects in animal models (Heffernan 2000). A small number of human trials have explored its potential to reduce abdominal fat, but none have reached the scale or rigour required for FDA approval. A 2007 phase 2b trial (n=536) reported a modest reduction in weight compared to placebo, but the effect was not statistically significant for the primary endpoint. No subsequent phase 3 trials have been registered.
What the Current Evidence Actually Shows
Semaglutide's weight-loss efficacy is well-documented. A meta-analysis of the STEP 1–4 trials (Davies 2022) found a mean placebo-subtracted weight loss of 12.4% at week 68. The drug's mechanism, GLP-1 receptor agonism, slows gastric emptying and modulates appetite centres in the hypothalamus. These effects are dose-dependent and persist as long as the drug is taken. Discontinuation leads to weight regain, a pattern seen consistently across studies.
AOD-9604's proposed mechanism is distinct. It is a synthetic peptide mimicking the lipolytic domain of growth hormone, intended to stimulate fat breakdown without the diabetogenic effects of full-length growth hormone. In vitro studies show increased lipolysis in adipocytes (Ng 2000). However, human data are sparse. A 12-week trial in 300 obese subjects found a 2.1 kg greater weight loss with AOD-9604 than placebo, but the difference was not significant (p=0.08). A subsequent 24-week extension showed no additional benefit.
Bone health during weight loss is a concern, particularly for older adults at risk of osteoporosis. Semaglutide's effects on bone density are being investigated; early signals suggest no detrimental impact. AOD-9604 has not been studied for bone outcomes.
What's Missing from the Coverage Equation
Even with strong efficacy data, Medicare coverage for weight-loss drugs faces statutory barriers. The Medicare Modernization Act of 2003 explicitly excludes drugs for "anorexia, weight loss, or weight gain" from Part D coverage, though exceptions exist for medically accepted indications like diabetes. Legislative efforts to amend this exclusion have stalled. Without a change in law, semaglutide's access will remain limited to those with a secondary qualifying diagnosis.
AOD-9604 lacks the foundational evidence to even be considered. No long-term safety data exist in older adults. No cardiovascular outcomes trials have been conducted. The peptide is not FDA-approved for any indication, and it is sold only as a research chemical. This places it entirely outside the Medicare framework.
Other compounds like MOTS-c, tesamorelin, CJC-1295, and retatrutide are at various stages of investigation. Tesamorelin is FDA-approved for HIV-associated lipodystrophy but not for general obesity. Retatrutide, a triple agonist, has shown promising weight loss in phase 2 trials (Jastreboff 2023) but remains years from potential approval. None currently meet Medicare's evidentiary standards.
How to Read the Policy Landscape
Recent guidance from CMS allows Medicare Part D plans to cover anti-obesity medications when prescribed for an additional medically accepted indication, such as reducing cardiovascular risk. This has opened a narrow path for semaglutide. Plans are not required to cover it, and many impose prior authorisation or step therapy. The result is a patchwork: some beneficiaries gain access, while others do not.
AOD-9604 is not mentioned in any CMS guidance. It is not listed in the Part D formulary reference file. It cannot be prescribed through Medicare because it is not a prescription drug in the eyes of the FDA. Any use remains confined to research settings or unregulated purchase.
For researchers observing this space, the contrast is instructive. Semaglutide illustrates how robust trial data can shift policy incrementally. AOD-9604 illustrates how a compound can generate interest without generating the evidence needed for regulatory or payer acceptance.
The Honest Answer
Semaglutide is more accessible than it was two years ago, but only for a subset of Medicare beneficiaries. Those with established cardiovascular disease and obesity may find coverage through a Part D plan that has updated its formulary. The majority of people seeking weight loss alone will not be covered.
AOD-9604 is not accessible through Medicare in any form. It is not approved, not covered, and not supported by the kind of data that would change that status. The peptide remains a subject of experimental inquiry, not a clinical option.
Self-administration of unapproved compounds carries risks that are not fully characterised in the published literature.
Share This Article